Training-Ovary 01 (Connected Prehabiliation Pelvic Cancer Surgery): Multicenter Randomized Study Comparing Neoadjuvant Chemotherapy For Patients Managed For Ovarian Cancer With Or Without A Connected Pre-Habilitation Program

Eric Lambaudie, Cécile Bannier/Braticevic, Charlène Villaron/Goetgheluck,Christophe Zemmour,Jean-Marie Boher,Patrick Ben Soussan,Jihane Pakradouni,Clement Brun, Leonor Lopez Almeida,Patricia Marino

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER(2021)

引用 9|浏览22
暂无评分
摘要
Background Patients undergoing neoadjuvant chemotherapy before surgery for advanced ovarian cancer may have impaired functional capacity, nutritional status, and emotional well-being.Primary objective(s) TRAINING-01 aims to determine if a connected pre-habilitation program during neoadjuvant chemotherapy for patients treated for an advanced ovarian cancer will improve physical capacity before major abdomino-pelvic surgery.Study hypothesis A pre-habilitation program during neoadjuvant chemotherapy will bring a fitter patient to surgery and will decrease treatment morbidity and improve oncological outcomes.Trial design This study is a prospective, multi-center, phase III study. The pre-habilitation program consists of providing multi-dimensional support during neoadjuvant chemotherapy using connected devices. The control group will receive usual care.Major inclusion/exclusion criteria Eligible patients will be women with International Federation of Gynecology and Obstetrics stage III-IV advanced ovarian cancer undergoing neoadjuvant chemotherapy. Patients must be able to perform a cardiopulmonary exercise test.Primary endpoint(s) The primary endpoint will be the comparison of the variation in maximum oxygen uptake (VO2 max) between baseline and surgery in the pre-habilitation group and control groups.Sample size 136 patients (68 per arm) will be recruited to demonstrate a medium standardized effect d=0.5 in the variations of VO2 max between baseline and surgery.Estimated dates for completing accrual and presenting results The duration of the study includes 24 months of recruitment and 5 years of follow up. We anticipate reporting primary endpoint results in 2024.
更多
查看译文
关键词
ovarian cancer
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要